


PARP-2-IN-2

Cat. No.:	HY-151624
CAS No.:	2915651-00-0
Molecular Formula:	C ₂₀ H ₂₂ ClN ₃ O ₂
Molecular Weight:	371.86
Target:	PARP; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PARP-2-IN-2 (compound 27) is a PARP2 inhibitor with an IC ₅₀ value of 0.057 μM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer ^[1] .																		
IC₅₀ & Target	IC ₅₀ : 0.057 μM (PARP2), 11.32 μM (MDA-MB-231 cells), 16.70 μM (MCF-7 cells) ^[1]																		
In Vitro	<p>PARP-2-IN-2 (0-1 μM; 1 h) inhibits PARP2 with an IC₅₀ value of 0.057 μM^[1].</p> <p>PARP-2-IN-2 (0-100 μM; 24 h) shows cytotoxicity to MDA-MB-231 and MCF-7 cancer cells^[1].</p> <p>PARP-2-IN-2 (16.7 μM; 24 h) induces cell cycle arrest and apoptosis^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MDA-MB-231 and MCF-7 cell lines</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed in vitro cytotoxicity to MDA-MB-231 and MCF-7 cells with IC₅₀ values of 11.32 and 16.70 μM, respectively.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 cell line</td> </tr> <tr> <td>Concentration:</td> <td>16.70 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Induced cell cycle arrest at G1/S phase with cells in pre-G1 phase increased from 1.85 to 25.91%.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 cell line</td> </tr> </table>	Cell Line:	MDA-MB-231 and MCF-7 cell lines	Concentration:	0-100 μM	Incubation Time:	24 h	Result:	Showed in vitro cytotoxicity to MDA-MB-231 and MCF-7 cells with IC ₅₀ values of 11.32 and 16.70 μM, respectively.	Cell Line:	MCF-7 cell line	Concentration:	16.70 μM	Incubation Time:	24 h	Result:	Induced cell cycle arrest at G1/S phase with cells in pre-G1 phase increased from 1.85 to 25.91%.	Cell Line:	MCF-7 cell line
Cell Line:	MDA-MB-231 and MCF-7 cell lines																		
Concentration:	0-100 μM																		
Incubation Time:	24 h																		
Result:	Showed in vitro cytotoxicity to MDA-MB-231 and MCF-7 cells with IC ₅₀ values of 11.32 and 16.70 μM, respectively.																		
Cell Line:	MCF-7 cell line																		
Concentration:	16.70 μM																		
Incubation Time:	24 h																		
Result:	Induced cell cycle arrest at G1/S phase with cells in pre-G1 phase increased from 1.85 to 25.91%.																		
Cell Line:	MCF-7 cell line																		

Concentration:	16.70 μ M
Incubation Time:	24 h
Result:	Induced potent apoptotic and weak necrotic effect in MCF-7 breast cancer cell line.

REFERENCES

[1]. El-Ghobashy NM, et al. Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer. Sci Rep. 2022 Sep 28;12(1):16246.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA